Health Care

Pharmaceutical Industry

Pharmaceutical Industry

NERA has provided economic analysis in testimony and written reports to many of the leading international research-based and generic pharmaceutical companies. We have performed competitive analyses of proposed acquisitions involving pharmaceutical companies as well as estimated damages or costs in contract, antitrust, patent, and regulatory matters. We also have expertise in providing companies with economically sound transfer pricing methodologies and strategic planning advice. Our work has encompassed both chemical based and biotechnology products. In our pharmaceutical work, we have:

  • Analyzed market definition and entry conditions in horizontal mergers involving pharmaceutical manufacturers as well as pharmaceutical wholesalers;
  • Analyzed the competitive impact of pharmaceutical companies acquiring pharmaceutical benefit managers;
  • Calculated damages in a wide variety of antitrust, contract dispute, and other matters;
  • Assessed market definition, market share, and entry conditions in antitrust counter-claims;
  • Made presentations to the federal antitrust agencies on the competitive effects of brand elimination and innovation markets;
  • Advised pharmaceutical companies on the business implications of competitive trends, regulatory changes, and health care reform;
  • Conducted public policy studies on intellectual property protection, parallel trade, health care reform, Medicare prescription drug proposals, and pricing investigations as they affect the pharmaceutical industry.

NERA also participates in policy discussions concerning the risks and returns of pharmaceutical research and development, and advises pharmaceutical companies on the business implications of competition, regulation, and health care reform. Our economists analyze emerging public policy issues such as the effects of regulatory delays in approving pharmaceutical products on public health and consequences of developing countries ignoring TRIPS standards on local pharmaceutical industry growth. 
Our experts also are experienced in the assessment of economic costs and benefits of therapeutic studies, the comparative evaluation of alternative means for controlling pharmaceutical costs by competitive and regulatory means, and assistance in evaluating reimbursement methodologies.

Please click here for more information about the firm's expertise in the pharmaceutical industry. 

Name Title Location Phone Email
Dr. Graeme Hunter Senior Managing Director New York City +1 212 345 7724
Dr. Christine Siegwarth Meyer Senior Managing Director
Chair of NERA's Intellectual Property Practice
White Plains, NY +1 914 448 4119
Dr. Subramaniam (Subbu) Ramanarayanan Senior Managing Director New York City
Los Angeles
+1 212 345 0745
+1 213 346 3038
Dr. Ramsey Shehadeh Senior Managing Director Washington, DC +1 212 345 6089
Dr. Paul Wong Managing Director San Francisco +1 415 291 1030
Dr. Emily Walden Director Washington, DC +1 202 466 9220
Brigid Jung Senior Consultant New York City +1 212 345 7039
Dr. Thomas McCarthy Affiliated Consultant Los Angeles +1 213 346 3000
Title Type Author
The Algorithmic Accountability Act: Potential Coverage Gaps in the Healthcare Sector Published Article Dr. Andrew Stivers and Dr. Gabriella Monahova
The Role of Rebates in the Pharmaceutical Industry Published Article Dr. Chris Stomberg
Non-Compete Agreements: Might They Be Procompetitive in Health Care? Published Article Dr. Paul Wong and Dr. Emily Walden
Drug Rebates: A Peek Behind the Curtain at Drug Prices Published Article Dr. Christopher Stomberg
Taking Stock of the Efficiencies Defense: Lessons from Recent Health Care Merger Revi... Published Article Dr. Subramaniam Ramanarayanan
Paper Trail: Review of a Recent Working Paper on the Effect of Copay Coupons on Drug ... Published Article Bryan Ray and Dr. Subbu Ramanarayanan
High Court Brings Economics Back To Pay-For-Delay Analysis Published Article By Dr. Sumanth Addanki, Dr. Alan Daskin, and Dr. Christine Siegwarth Meyer
How Much Does that Medication Cost? A Study of Medicare Beneficiaries' Knowledge of O... Study By Dr. Eugene Ericksen and Melissa Pittaoulis
An Analysis of Price Effects from Drug Shortages for Independent Pharmacies and the P... Working Paper By Dr. Graeme Hunter
Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development E... Working Paper By Dr. Graeme Hunter with Dr. John Vernon and Dr. Joseph Cook